As the song goes, the Food and Drug Administration’s (“FDA’s”) 2024 Final Rule regulating laboratory-developed tests (“LDTs”) as medical devices (“Final Rule”), is not merely dead—it’s really most sincerely dead.

Perhaps not for good, but for the foreseeable future, at least.

The FDA has let the clock run out on the 60-day time period to appeal the March 31, 2025, decision by the U.S. District Court for the Eastern District of Texas concluding that: 1) the FDA overstepped its authority, and 2) the LDT Final Rule of May 6, 2024, was unlawful. As we explained at that time, the Final Rule would have required virtually all clinical laboratories offering their own LDTs to comply with FDA expectations for medical device manufacturers in phases over a four-year period—with the first compliance deadlines set for May 2025.

The March 2025 opinion by Judge Sean D. Jordan vacated the controversial Final Rule a little more than a month before the first implementation deadlines were to take effect, and remanded the issue back to the FDA.

Now, absent an appeal, it is not likely that the last remaining option to salvage the Final Rule—i.e., congressional action—will happen in the current political climate.

As we explained at the time of its release, the 2024 Final Rule followed more than a decade of uncertainty as to the course of action the agency would take with respect to LDTs. When it came, the Final Rule escaped potential rollback by a future presidential administration as a “midnight rule” under the Congressional Review Act—yet threw clinical labs into nearly a year of putting time and resources into their strategy for compliance.

As we anticipated, the Supreme Court’s June 28, 2024, decision in Loper Bright Enterprises v. Raimondoending Chevron deference to agencies when interpreting ambiguous statutes—made it easier for entities to challenge both FDA authority and the validity of the agency’s Final Rule. The American Clinical Laboratory Association and the Association for Molecular Pathology filed suit in federal district court in Texas on May 29, 2024, and August 19, 2024, respectively.

But perhaps no one could have anticipated the extent to which the FDA itself has changed in the lifespan of the LDT Final Rule—with unprecedented staff cutbacks, changing policies and priorities, and a continued emphasis on deregulation at the federal level that is not likely to change until a future presidential administration rolls in. States, meanwhile, continue to regulate LDTs to some extent, and the FDA continues to have authority to regulate certain components of LDTs (such as reagents and collection devices), as well as in vitro diagnostics. While this particular chapter on LDTs has drawn to a close, we aren’t going anywhere—and we will continue to advise our lab clients on state as well as remaining federal compliance considerations.


Epstein Becker Green Staff Attorney Ann W. Parks contributed to the preparation of this post.

Back to Health Law Advisor Blog

Search This Blog

Blog Editors

Authors

Related Services

Topics

Archives

Jump to Page

Subscribe

Sign up to receive an email notification when new Health Law Advisor posts are published:

Privacy Preference Center

When you visit any website, it may store or retrieve information on your browser, mostly in the form of cookies. This information might be about you, your preferences or your device and is mostly used to make the site work as you expect it to. The information does not usually directly identify you, but it can give you a more personalized web experience. Because we respect your right to privacy, you can choose not to allow some types of cookies. Click on the different category headings to find out more and change our default settings. However, blocking some types of cookies may impact your experience of the site and the services we are able to offer.

Strictly Necessary Cookies

These cookies are necessary for the website to function and cannot be switched off in our systems. They are usually only set in response to actions made by you which amount to a request for services, such as setting your privacy preferences, logging in or filling in forms. You can set your browser to block or alert you about these cookies, but some parts of the site will not then work. These cookies do not store any personally identifiable information.

Performance Cookies

These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.